Abstract. Absence of neoplastic disease in the organ-recipient is required in order to allow organ transplantation. Due to its rarity, no data regarding management of patients with Multiple endocrine neoplasia type 1 (MEN1) and end-stage renal failure candidates for kidney transplantation are available. A 36 year-old man was referred to the present hospital with MEN1, with a neuroendocrine pancreatic tumor and primary hyperparathyroidism and associated Alport syndrome with end stage renal failure. The present study aimed to establish the eligibility of the patient for a kidney transplantation. The neuroendocrine tumor had been treated with duodenopancreatectomy two years earlier and hyperparathyroidism by parathyroidectomy. The review of the literature did not provide data regarding the eligibility for kidney transplantation of patients harboring a neuroendocrine pancreatic tumor in the context of MEN1. Due to the end-stage renal failure, neuroendocrine markers were unreliable and the investigation therefore relied on imaging studies, which were unremarkable. Young age, low-grade tumor, low expression of Ki67, absence of metastatic lymph nodes, onset in the setting of a MEN1 were all positive prognostic factors of the neuroendocrine tumor. Normal serum calcium ruled out persistent primary hyperparathyroidism. Overall, hemodyalisis is known to significantly reduce life expectancy. Benefits of kidney transplantation overcome the risk of neuroendocrine tumor recurrence in a young patient bearing MEN1.
IntroductionMultiple endocrine neoplasia type 1 (MEN1), is a rare autosomal dominant disease, linked to a mutation of a tumor suppressor gene encoding for the protein menin. Tumors occur in parathyroids, pancreas and pituitary, with a variable phenotype. Alport syndrome, a recessive X-linked disease is due to mutations of the genes, encoding for the procollagen IV, usually leading to end-stage chronic kidney disease. Neurosensory deafness, abnormally colored retina and misshapen lenses are the other most relevant features of the syndrome. The patient we describe herein was carrying both these rare diseases. The clinical challenge we had to face was to establish the eligibility of the patient to kidney and possibly pancreas transplantation.
Case reportWe report on a 36 year-old man affected by MEN1, namely with primary hyperparathyroidism (PHPT) and non-secreting neuroendocrine pancreatic tumor and concomitant Alport syndrome with end-stage chronic kidney disease. At the age of 10, following the diagnosis of Alport syndrome in the mother's lineage, the patient underwent a kidney biopsy which showed a histologic picture of Alport syndrome. Five years later, because of increasing proteinuria, angiotensin converting enzyme inhibitor treatment was started. The renal function progressively deteriorated up to end-stage renal failure and, at the age of 32, hemodialysis was started. The diagnosis of Alport syndrome was confirmed by genetic analysis. Familial PHPT was diagnosed in his father's kindred when the patient was 30 ye...